Dr. Kantarjian on 40 years of progress in CML care
In this engaging discussion, Dr. Nitin Jain interviews Dr. Hagop Kantarjian, a global pioneer in leukemia care, about groundbreaking advancements in leukemia and
Meeting News
The Twelfth Annual Meeting of the Society of Hematologic Oncology
Video Interviews
Leukemia
News
FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation
The US Food and Drug Administration (FDA) has approved revumenib for relapsed or refractory acute leukemia with KMT2A translocation in adult and pediatric patients
Myelodysplastic Syndromes
News
FDA approves luspatercept in adult patients with low-risk MDS
On August 28, 2023, the US Food and Drug Administration (FDA) approved luspatercept-aamt (Reblozyl) as a first-line treatment for anemia in adult patients
Lymphoma
Indolent B-Cell Lymphomas
News
Epcoritamab shows ‘clinically meaningful activity’ in EPCORE NHL primary analysis
Epcoritamab monotherapy showed a “manageable safety profile” and “clinically meaningful activity” in patients with relapsed or refractory follicular lymphoma who had at least
Meeting News
The Twelfth Annual Meeting of the Society of Hematologic Oncology
Video Interviews
Drs. Shah, Jain discuss CAR-T cell therapy advances
In this video interview, Bijal Shah, MD, of the Moffitt Cancer Center and Nitin Jain, MD, of the University of Texas MD
Leukemia
Acute Myeloid Leukemia
News
How does asciminib compare with TKIs in CML?
Patients with newly diagnosed chronic myeloid leukemia (CML) showed better response rates and higher safety when treated with asciminib compared with standard tyrosine
Society Updates
SOHO Announces SEHH/SETH Joint Session With Dr. Garcia-Manero
The Society of Hematologic Oncology (SOHO) will be holding a joint session with two Spain-based hematology societies: la Sociedad Española de Hematología y
Myelodysplastic Syndromes
News
Primary analysis finds luspatercept reduces transfusion dependence in lower-risk MDS
Luspatercept is more effective than epoetin alfa in achieving transfusion independencin anemia patients with lower-risk myelodysplastic syndromes (MDS), according to a primary analysis
Leukemia
Acute Lymphoblastic Leukemia
Salvage therapies show high remission rate in relapsed Ph+ ALL
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who relapsed after frontline ponatinib-based therapies had a high response rate to salvage treatments,
Educational Resources
The Twelfth Annual Meeting of the Society of Hematologic Oncology
Meet-the-Professor session with Natalie Callander, MD
This Meet-the-Professor session in multiple myeloma is delivered by Natalie Callander, MD, of the University of Wisconsin. Dr. Callander as part of the